11 October 2016 - Deborah Wilkes
Archived
Johnson & Johnson is set to acquire the rights to AstraZeneca's Rhinocort Aqua nasal spray outside the US in a deal worth US$330 million.
New to OTCToolbox?
This is available as part of an Annual Subscription to the OTCToolbox website.